ESALF - Eisai: All About Lenvima And Leqembi
2024-03-17 07:26:15 ET
Summary
- Don't be fooled by the high multiples for Eisai, since high probability growth is incoming.
- Lenvima and Leqembi should continue to deliver, and Eisai is well positioned with its strategic partnerships.
- Particularly, Leqembi, which is on the cusp of commercialization, has major horizon in China and the US.
- Assuming growth in Lenvima to 2025 targets, to justify a fair valuation at today's price, Leqembi doesn't even have to penetrate deep assuming the US were its only market.
- Looks like a reasonably valued grower.
On a trailing basis, Eisai ( OTCPK:ESALF ) looks like not much more than a pretty high multiple Japanese specialty pharma stock with large exposures in oncology and neurology....
Eisai: All About Lenvima And Leqembi